John C Kane

US Patent:

6822532, Nov 23, 2004

Filed:

Jul 29, 2002

Appl. No.:

10/207670

Inventors:

John R. Kane - Natick MA
Richard J. Garabedian - Bedford NH

Assignee:

Sage Laboratories, Inc. - Natick MA

International Classification:

H01P 308

US Classification:

333116, 333115, 333238, 333244, 333246

Abstract:

A suspended stripline device and method for manufacturing thereof. The device includes first and second conductive traces disposed on a dielectric substrate, each of the first and second conductive traces having a first edge and a second edge, and a housing at least partially surrounding the dielectric substrate, wherein the second edge of each of the first and second conductive traces includes at least one outwardly extending protrusion, the size and orientation of which may be selected so as to compensate for unequal even and odd mode propagation velocities through the suspended-stripline device. The device may be packaged by folding solder-coated tabs, provided on the housing, around the dielectric substrate and heating the device such that the solder melts causing the housing to be secured to the substrate.

US Patent:

8399512, Mar 19, 2013

Filed:

Nov 24, 2008

Appl. No.:

12/276856

Inventors:

Laura C. Akullian - Belmont MA, US
Russell C. Petter - Stow MA, US
John J. Kane - Queens Village NY, US
Charles E. Hammond - Billerica MA, US
Mao Yin - Needham MA, US
Aleksandr Yurkovetskiy - Littleton MA, US
Cheri A. Stevenson - Haverhill MA, US

Assignee:

Mersana Therapeutics, Inc. - Cambridge MA

International Classification:

A61K 31/335
C07D 303/00

US Classification:

514475, 549332

Abstract:

Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog.

US Patent:

20050176761, Aug 11, 2005

Filed:

Dec 7, 2004

Appl. No.:

11/006042

Inventors:

Marko Pregel - Arlington MA, US
Bradford Hirth - Littleton MA, US
John Kane - Maynard MA, US
Shuang Qiao - San Diego CA, US
Jill Gregory - Acton MA, US
Lisa Cuff - Leominster MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K031/4709
A61K031/47

US Classification:

514310000

Abstract:

Tetrhydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.

US Patent:

20070254894, Nov 1, 2007

Filed:

Jan 9, 2007

Appl. No.:

11/651406

Inventors:

John Kane - Maynard MA, US
Bradford Hirth - Littleton MA, US
Christopher Yee - Needham MA, US
Mark Staveski - Taunton MA, US
Hans-Peter Biemann - Cambridge MA, US
Marko Pregel - Arlington MA, US

International Classification:

A61K 31/4709
A61K 31/497
A61P 9/00
C07D 215/38
C07D 243/08
C07D 401/14
C07D 413/14

US Classification:

514253060, 514314000, 540575000, 544128000, 544238000, 544353000, 544363000, 546171000

Abstract:

Disclosed herein are angiogenesis inhibitors represented by formula (I) or formula (II): The variables for formulas (I) and (II) are defined herein.

US Patent:

53156358, May 24, 1994

Filed:

Sep 30, 1992

Appl. No.:

7/954106

Inventors:

John R. Kane - Wellington FL
Robert J. Schwendeman - Pompano Beach FL
James A. Wright - Coral Springs FL

Assignee:

Motorola, Inc. - Schaumburg IL

International Classification:

H04M 1100

US Classification:

379 57

Abstract:

A method and apparatus for reliably delivering messages (200) from a central terminal (102) to a communication receiver (130) in a communication system (100), such as an electronic mail system. The central terminal (102) sequentially transmits messages (200) to the communication receiver (130) and the communication receiver (130) receives transmitted messages (200) over a first communication medium (122). The communication receiver (130) reconciles messages that it failed to receive over the first communication medium (122) with the central terminal (102) over a second communication medium (152). The reconciliation between the communication receiver (130) and the central terminal (102) utilizes message sequence identifiers (208) transmitted with the messages (200) that identify the transmission sequence of the sequentially transmitted messages (200).

US Patent:

53945603, Feb 28, 1995

Filed:

Sep 30, 1992

Appl. No.:

7/954634

Inventors:

John R. Kane - Wellington FL

Assignee:

Motorola, Inc. - Schaumburg IL

International Classification:

H04B 7185

US Classification:

455 121

Abstract:

A multi-regional message delivery system (100) delivers messages from a central hub (108) to a number of message transmission regions (102,104,106) for transmission of the messages therein. The central hub 108) receives messages, encodes the messages, and transmits the encoded messages in a number of message data pipes (304) in a message delivery signal (302). A satellite (122) receives the transmitted message delivery signal (302) and then transmits the message delivery signal (302) to a number of regional stations (130,132,134) located in the message transmission regions. The regional stations receive the transmitted message delivery signal (302), select at least one of the data pipes (304) in the message delivery signal (302), and transmit the encoded messages within the message transmission regions.

US Patent:

54871000, Jan 23, 1996

Filed:

May 17, 1994

Appl. No.:

8/248853

Inventors:

John R. Kane - Wellington FL

Assignee:

Motorola, Inc. - Schaumburg IL

International Classification:

H04M 1100

US Classification:

379 57

Abstract:

An electronic mail message delivery system (100) includes an electronic mail network (113) for delivering electronic mail messages from originating devices to destination devices, the electronic mail messages including network addresses (212) for identifying originating and destination devices communicating the electronic mail messages, and including message data (214). A paging terminal (102) is coupled to the electronic mail network (113) for receiving the electronic mail messages, storing the received electronic mail messages including alias identification (208,210) of the originating devices of the electronic mail messages, and encoding messages including the message data and the alias of the received electronic mail messages for transmission to at least one selective call receiver (130). A paging transmitting means (124,126) transmits the encoded messages over a paging communication channel, and at least one portable selective call receiver (130) can receive the transmitted messages. Optionally, the at least one portable selective call receiver (130) can transmit a reply message through the paging terminal (102) to an originating device on the electronic mail network (113).

US Patent:

20200030360, Jan 30, 2020

Filed:

Dec 5, 2017

Appl. No.:

16/466927

Inventors:

- Newton MA, US
John James Kane - Cambridge MA, US
James Michael Siedlecki - Burlington MA, US
Zuzana Dostalova - Cambridge MA, US
Ifat Rubin-Bejerano - Newton MA, US
Hua Miao - Newton MA, US
Eric Steven Furfine - Lincoln MA, US

International Classification:

A61K 31/716
A61K 47/61
C07K 16/28
C07K 16/32

Abstract:

The present invention encompasses embodiments in which a therapeutic antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more β-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such β-1,6-glucan conjugates. In certain embodiments, a β-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.